222 590

Cited 7 times in

Higher serum interleukin-17A levels as a potential biomarker for predicting early disease progression in patients with hepatitis B virus-associated advanced hepatocellular carcinoma treated with sorafenib

Authors
Cho, HJ  | Kim, SS  | Nam, JS | Oh, MJ | Kang, DR | Kim, JK  | Lee, JH  | Kim, B  | Yang, MJ  | Hwang, JC  | Lim, SG  | Shin, SJ  | Lee, KM  | Yoo, BM  | Lee, KJ  | Cho, SW  | Cheong, JY
Citation
Cytokine, 95. : 118-125, 2017
Journal Title
Cytokine
ISSN
1043-46661096-0023
Abstract
BACKGROUND: Although sorafenib is the only available drug with proven efficacy for patients with advanced hepatocellular carcinoma (HCC), the clinical efficacy of sorafenib is variable and unpredictable. The aim of the current study was to identify potential serum biomarkers predicting cancer progression and overall survival (OS) in patients with hepatitis B virus (HBV)-related advanced HCC treated with sorafenib.
METHODS: Thirty-four patients with HBV-related advanced HCC (modified Union for International Cancer Control [UICC] stage IVa or IVb) treated with sorafenib for more than 4weeks were retrospectively enrolled. Using a Luminex 200 system, 11 cytokines including interleukin-17A (IL-17A) were measured in baseline serum samples prior to sorafenib administration. Several clinical factors and the serum concentrations of the 11 cytokines were analyzed using Cox regression analysis.
RESULTS: In the analysis of progression-free survival (PFS), older age (year: hazard ratio [HR]=1.07: 95% confidence interval [CI]=1.00-1.15: P=0.046) and higher baseline serum IL-17A level (>1.94pg/mL: HR=19.96: 95% CI=3.32-119.86: P=0.001) were identified as significant risk factors for early progression with good predictive power (Harrell's C=0.817, standard error estimates (se)=0.085). In the analysis of OS, higher Child-Pugh score (>5: HR=2.35, 95% CI=1.09-5.10, P=0.030) and lower serum baseline fibroblast growth factor-2 level (CONCLUSION: A higher serum IL-17A level is a potential biomarker for predicting poor PFS in patients with HBV-related advanced HCC treated with sorafenib.
MeSH

DOI
10.1016/j.cyto.2017.02.020
PMID
28260649
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Gastroenterology
Journal Papers > School of Medicine / Graduate School of Medicine > Radiology
Ajou Authors
김, 보현  |  김, 순선  |  김, 재근  |  신, 성재  |  양, 민재  |  유, 병무  |  이, 광재  |  이, 기명  |  이, 제희  |  임, 선교  |  정, 재연  |  조, 성원  |  조, 효정  |  황, 재철
Files in This Item:
28260649.pdfDownload
Export

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse